<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563368</url>
  </required_header>
  <id_info>
    <org_study_id>OB-301</org_study_id>
    <nct_id>NCT00563368</nct_id>
  </id_info>
  <brief_title>A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults</brief_title>
  <official_title>A Phase III, Randomized, Double-Blind, Parallel-Design Study Comparing Multiple Doses of VI-0521 to Placebo and Their Single-Agent Phentermine and Topiramate Constituents for the Treatment of Obesity in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VIVUS, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>VIVUS, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of various doses of
      VI-0521 compared to both placebo, and the single-agent components that comprise each
      combination dose. This study will provide confirmatory data to demonstrate that doses of
      VI-0521 have efficacy that is greater than placebo and each of the single-agent components
      that comprise the combination dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Weight Loss From Baseline to Week 28</measure>
    <time_frame>baseline to 28 weeks</time_frame>
    <description>Percent weight loss from baseline to Week 28 with last observation carried forward (LOCF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF</measure>
    <time_frame>baseline to 28 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">756</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>VI-0521 Top</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VI-0521; high dose phentermine/topiramate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VI-0521 Mid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VI-0521; mid dose phentermine/topiramate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPM 46</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mid dose topiramate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPM 92</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose topiramate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHEN 7.5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mid dose phentermine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHEN 15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>high dose phentermine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>phentermine 15 mg and topiramate 92 mg, po once daily</description>
    <arm_group_label>VI-0521 Top</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>phentermine 7.5 mg and topiramate 46 mg, po once daily</description>
    <arm_group_label>VI-0521 Mid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topiramate</intervention_name>
    <description>topiramate 46 mg, po once daily</description>
    <arm_group_label>TPM 46</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topiramate</intervention_name>
    <description>topiramate 92 mg, po once daily</description>
    <arm_group_label>TPM 92</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phentermine</intervention_name>
    <description>phentermine 7.5 mg, po once daily</description>
    <arm_group_label>PHEN 7.5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>phentermine</intervention_name>
    <description>phentermine 15 mg, po once daily</description>
    <arm_group_label>PHEN 15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VI-0521</intervention_name>
    <description>placebo, po once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  70 years of age or less with body mass index (BMI) between 30 and 45 kg/m2

          -  Informed Consent

          -  Females of child-bearing potential must be using adequate contraception

        Exclusion Criteria:

          -  Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months

          -  Clinically significant renal, hepatic or psychiatric disease

          -  Unstable thyroid disease or replacement therapy

          -  Nephrolithiasis

          -  Obesity of known genetic or endocrine origin

          -  Participation in a formal weight loss program or lifestyle intervention

          -  Glaucoma or elevated intraocular pressure

          -  Pregnancy or breastfeeding

          -  Drug or Alcohol abuse

          -  Smoking cessation within previous 3 months or plans to quit smoking during study

          -  Eating disorders within past year

          -  Cholelithiasis within past 6 months

          -  Type 2 diabetes

          -  Previous bariatric surgery

          -  Bipolar disorder or psychosis

          -  Steroid hormone therapy not stable for 3 months

          -  Systolic blood pressure &gt; 160 mmHg, diastolic blood pressure &gt; 100 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Peterson</last_name>
    <role>Study Director</role>
    <affiliation>VIVUS, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kishore Gadde, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <results_first_submitted>July 31, 2012</results_first_submitted>
  <results_first_submitted_qc>July 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 3, 2012</results_first_posted>
  <disposition_first_submitted>November 18, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 18, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 20, 2009</disposition_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topiramate</mesh_term>
    <mesh_term>Phentermine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject recruitment occurred at investigative sites in the US between November 2007 through January 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="P2">
          <title>PHEN 7.5 mg</title>
          <description>7.5 mg phentermine</description>
        </group>
        <group group_id="P3">
          <title>TPM 46 mg</title>
          <description>46 mg topiramate</description>
        </group>
        <group group_id="P4">
          <title>VI-0521 Mid</title>
          <description>7.5 mg/46 mg phentermine/topiramate</description>
        </group>
        <group group_id="P5">
          <title>PHEN 15 mg</title>
          <description>15 mg phentermine</description>
        </group>
        <group group_id="P6">
          <title>TPM 92 mg</title>
          <description>92 mg topiramate</description>
        </group>
        <group group_id="P7">
          <title>VI-0521 Top</title>
          <description>15 mg/92 mg phentermine/topiramate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="107"/>
                <participants group_id="P5" count="108"/>
                <participants group_id="P6" count="107"/>
                <participants group_id="P7" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="78"/>
                <participants group_id="P5" count="80"/>
                <participants group_id="P6" count="77"/>
                <participants group_id="P7" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="29"/>
                <participants group_id="P5" count="28"/>
                <participants group_id="P6" count="30"/>
                <participants group_id="P7" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>protocol non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>requirement for restricted medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B2">
          <title>PHEN 7.5 mg</title>
          <description>7.5 mg phentermine</description>
        </group>
        <group group_id="B3">
          <title>TPM 46 mg</title>
          <description>46 mg topiramate</description>
        </group>
        <group group_id="B4">
          <title>VI-0521 Mid</title>
          <description>7.5 mg/46 mg phentermine/topiramate</description>
        </group>
        <group group_id="B5">
          <title>PHEN 15 mg</title>
          <description>15 mg phentermine</description>
        </group>
        <group group_id="B6">
          <title>TPM 92 mg</title>
          <description>92 mg topiramate</description>
        </group>
        <group group_id="B7">
          <title>VI-0521 Top</title>
          <description>15 mg/92 mg phentermine/topiramate</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="107"/>
            <count group_id="B5" value="108"/>
            <count group_id="B6" value="107"/>
            <count group_id="B7" value="108"/>
            <count group_id="B8" value="756"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="11.43"/>
                    <measurement group_id="B2" value="46.4" spread="11.57"/>
                    <measurement group_id="B3" value="46.9" spread="12.62"/>
                    <measurement group_id="B4" value="44.6" spread="11.07"/>
                    <measurement group_id="B5" value="45.7" spread="12.38"/>
                    <measurement group_id="B6" value="45.8" spread="11.21"/>
                    <measurement group_id="B7" value="44.6" spread="12.84"/>
                    <measurement group_id="B8" value="45.6" spread="11.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="86"/>
                    <measurement group_id="B6" value="85"/>
                    <measurement group_id="B7" value="85"/>
                    <measurement group_id="B8" value="599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="23"/>
                    <measurement group_id="B8" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="108"/>
                    <measurement group_id="B6" value="107"/>
                    <measurement group_id="B7" value="108"/>
                    <measurement group_id="B8" value="756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Weight Loss From Baseline to Week 28</title>
        <description>Percent weight loss from baseline to Week 28 with last observation carried forward (LOCF)</description>
        <time_frame>baseline to 28 weeks</time_frame>
        <population>Intent-to-treat Last-observation-carried-forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>PHEN 7.5 mg</title>
            <description>7.5 mg phentermine</description>
          </group>
          <group group_id="O3">
            <title>TPM 46 mg</title>
            <description>46 mg topiramate</description>
          </group>
          <group group_id="O4">
            <title>VI-0521 Mid</title>
            <description>7.5 mg/46 mg phentermine/topiramate</description>
          </group>
          <group group_id="O5">
            <title>PHEN 15 mg</title>
            <description>15 mg phentermine</description>
          </group>
          <group group_id="O6">
            <title>TPM 92 mg</title>
            <description>92 mg topiramate</description>
          </group>
          <group group_id="O7">
            <title>VI-0521 Top</title>
            <description>15 mg/92 mg phentermine/topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Weight Loss From Baseline to Week 28</title>
          <description>Percent weight loss from baseline to Week 28 with last observation carried forward (LOCF)</description>
          <population>Intent-to-treat Last-observation-carried-forward (ITT-LOCF)</population>
          <units>percent weight loss</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="106"/>
                <count group_id="O6" value="105"/>
                <count group_id="O7" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.61"/>
                    <measurement group_id="O2" value="5.5" spread="0.61"/>
                    <measurement group_id="O3" value="5.1" spread="0.61"/>
                    <measurement group_id="O4" value="8.5" spread="0.62"/>
                    <measurement group_id="O5" value="6.1" spread="0.61"/>
                    <measurement group_id="O6" value="6.4" spread="0.62"/>
                    <measurement group_id="O7" value="9.2" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.831</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>4.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.825</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.53</ci_lower_limit>
            <ci_upper_limit>4.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>7.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.830</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.86</ci_lower_limit>
            <ci_upper_limit>9.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.832</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>4.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.828</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.38</ci_lower_limit>
            <ci_upper_limit>4.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.831</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.11</ci_lower_limit>
            <ci_upper_limit>8.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF</title>
        <time_frame>baseline to 28 weeks</time_frame>
        <population>Intent-to-treat Last-observation-carried-forward (ITT-LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>PHEN 7.5 mg</title>
            <description>7.5 mg phentermine</description>
          </group>
          <group group_id="O3">
            <title>TPM 46 mg</title>
            <description>46 mg topiramate</description>
          </group>
          <group group_id="O4">
            <title>VI-0521 Mid</title>
            <description>7.5 mg/46 mg phentermine/topiramate</description>
          </group>
          <group group_id="O5">
            <title>PHEN 15 mg</title>
            <description>15 mg phentermine</description>
          </group>
          <group group_id="O6">
            <title>TPM 92 mg</title>
            <description>92 mg topiramate</description>
          </group>
          <group group_id="O7">
            <title>VI-0521 Top</title>
            <description>15 mg/92 mg phentermine/topiramate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 5% Weight Loss at Week 28 With LOCF</title>
          <population>Intent-to-treat Last-observation-carried-forward (ITT-LOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="104"/>
                <count group_id="O3" value="102"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="106"/>
                <count group_id="O6" value="105"/>
                <count group_id="O7" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="39.2"/>
                    <measurement group_id="O4" value="62.1"/>
                    <measurement group_id="O5" value="46.2"/>
                    <measurement group_id="O6" value="48.6"/>
                    <measurement group_id="O7" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0140</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5832</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.154</ci_lower_limit>
            <ci_upper_limit>3.563</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.246</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6418</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.283</ci_lower_limit>
            <ci_upper_limit>3.932</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>10.623</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.6440</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.424</ci_lower_limit>
            <ci_upper_limit>20.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.568</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7391</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.460</ci_lower_limit>
            <ci_upper_limit>4.514</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0066</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6158</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.241</ci_lower_limit>
            <ci_upper_limit>3.781</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>With 100 subjects in each of the seven arms in this trial, the trial has more than 90% power to detect a difference of at least 3.1% between combination and monotherapy or placebo treatment assuming a standard deviation of 5.3% and a significance level of 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Intersection-union method applied in a step-down testing approach</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.0857</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.650</ci_lower_limit>
            <ci_upper_limit>17.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from when written informed consent was provided through 28 days after the last dose of investigational product.</time_frame>
      <desc>Only subjects who received at least one dose of study drug were included in the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="E2">
          <title>PHEN 7.5 mg</title>
          <description>7.5 mg phentermine</description>
        </group>
        <group group_id="E3">
          <title>TPM 46 mg</title>
          <description>46 mg topiramate</description>
        </group>
        <group group_id="E4">
          <title>VI-0521 Mid</title>
          <description>7.5 mg/46 mg phentermine/topiramate</description>
        </group>
        <group group_id="E5">
          <title>PHEN 15 mg</title>
          <description>15 mg phentermine</description>
        </group>
        <group group_id="E6">
          <title>TPM 92 mg</title>
          <description>92 mg topiramate</description>
        </group>
        <group group_id="E7">
          <title>VI-0521 Top</title>
          <description>15 mg/92 mg phentermine/topiramate</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm of ampulia of vater</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="84" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="88" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After Sponsor's written notification that publication of results is no longer planned or 12 months after termination of the study at all sites, Institution &amp; PI may publish, upon written approval from Sponsor, results of the Study. Sponsor will be given the opportunity to review any proposed publication at least 60 days prior to submission for publication or disclosure. Upon Sponsor's written request, Institution and PI shall not publish or disclose information related to the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wesley W. Day PhD</name_or_title>
      <organization>Vivus, Inc.</organization>
      <phone>650-934-5200</phone>
      <email>day@vivus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

